A Phase I Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma
Latest Information Update: 08 Jan 2024
At a glance
- Drugs WT1 protein-specific T-cell therapy Atara/MSKCC (Primary) ; Busulfan; Fludarabine; Melphalan
- Indications Multiple myeloma; Plasma cell leukaemia
- Focus Adverse reactions
- 04 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 04 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 03 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.